These applications are reviewed regularly by an independent Advisory Team, of which the first three internationally-recognized scientific experts have been confirmed.
aiForward is an open, global program created by Aiforia, aiming to advance the use of AI-powered image analysis in medical research, focusing initially on neuroscience, cancer, and lifestyle diseases. The program was launched in December 2018 and has attracted wide international interest — receiving applications from institutes in Norway, the United States, and other countries. These applications are reviewed regularly by an independent Advisory Team, of which the first three internationally-recognized scientific experts have been confirmed.
aiForward’s Advisory Team’s first members are Professor Joseph Geradts from City of Hope National Medical Center, United States, Dr. Fredric Manfredsson from Michigan State University, United States, and Dr. Juha Kononen from the Department of Oncology at Central Finland Hospital. The Advisory Team evaluates the scientific validity of the proposals and provides expert insights and guidance on the selected research projects.
The three members bring together years of versatile experience from various positions held at some of the world’s most highly regarded institutes such as Oxford University and the Dana-Farber Cancer institute, in a wide range of clinical and molecular research fields from oncology to neuroscience.
Professor Geradts is a board-certified specialist in anatomical pathology and an accomplished cancer researcher and clinician, recently initiating several studies that utilize deep learning algorithms for the development of novel prognostic and predictive breast cancer models. "[Joining the Advisory Team] allows me to provide my input on research projects that may significantly advance the application of artificial intelligence in anatomic pathology. Aiforia has the potential to play a significant role in this area, which I consider critical to the future of pathology,” Professor Geradts comments on his new role in reviewing aiForward projects focused on cancer research.
Dr. Kononen is also collaborating with Aifoira to provide his advice and expertise in cancer. Dr. Kononen is a board-certified oncologist and leads the oncology department at a large hospital in Finland. Meanwhile Dr. Manfredsson, an assistant professor of Translational Science and Molecular Medicine, will provide his expertise to neuroscience led projects. He is currently pioneering research focusing on the engineering and application of viral vectors in the study and treatment of Parkinson’s disease.
Aiforia is excited to be collaborating with such accomplished researchers and clinicians in order to launch the first few projects to bring deep learning AI to the lab bench. AI and deep learning methods hold the promise of increased consistency and speed in the evaluation of pathologic specimens, and automated algorithms enable highly quantitative assessments,” says Professor Geradts, and continues, “They may also allow the identification and utilization of features in histologic or cytologic specimens that may be difficult to appreciate or quantify by the human eye and brain.” Aiforia as well is excited to observe and share the progress of these projects, and the momentous results that are sure to be generated through the use of AI.
Applications are accepted on a continuous basis in the fields of cancer, neuroscience, and lifestyle diseases. These can be submitted through the program website now at www.aiforward.org
For more information, please visit:
Program: aiforward.org
Technology and company: aiforia.com
Contact:
Emma Vehviläinen, Marketing Manager
tel +358 40 667 5204
About Fimmic and Aiforia® platform
Aiforia Technologies, founded in 2013, is a Helsinki, Finland based medical software company specialized in developing intelligent, cloud-based solutions for image-based diagnostics. Aiforia®'s unique platform brings together deep learning -based image analysis and high-performance cloud computing. The SaaS solution enables fast, accurate, and affordable image analysis support for medical experts through zero-friction cloud deployment and an intuitive user interface.
With the Aiforia® Create tool, the users can create deep learning AI algorithms to detect and quantify specific features of interest in images, reducing time to results, improving accuracy and reproducibility. Researchers can discover more in less time and generate quantified information from samples that have previously been analyzed with only manual, visual, and other subjective methods.
Aiforia Create tool is used today in various medical research and drug development projects in Europe and North America. In addition to digital pathology images, Aiforia is compatible with any other 2D images. Aiforia is currently sold with a research use status.
